Experimental Oncology Researchers work at the forefront of cancer research, focusing on discovering and developing new treatments and therapies for cancer. They conduct in-depth studies to understand the molecular and genetic foundations of cancer, including how tumors grow, spread, and develop resistance to existing treatments. These researchers test new drugs, immunotherapies, and targeted therapies in laboratory settings, often using preclinical models to simulate how human cancers respond to different treatments. Their innovative work is vital for uncovering novel treatment options that could be more effective and less toxic than traditional therapies like chemotherapy and radiation. Experimental oncology researchers are also involved in advancing early detection and personalized treatment strategies. By identifying specific genetic mutations, biomarkers, and molecular pathways unique to each patient’s cancer, they help tailor treatments to individual needs, ensuring better outcomes. These researchers are continuously working to refine diagnostic tools, improve precision medicine, and provide insights into overcoming drug resistance. Their contributions are instrumental in transforming the landscape of cancer care, offering hope for more effective, less invasive treatments that could significantly improve survival rates and quality of life for cancer patients. Furthermore, experimental oncology researchers collaborate with clinical teams to fast-track promising therapies from the lab to human trials, accelerating the path to approval. Their work also involves evaluating combination therapies, aiming to maximize treatment efficacy and overcome challenges posed by cancer's adaptability.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China